Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Immunovia AB ( (SE:IMMNOV) ) has issued an announcement.
Immunovia AB has published its 2025 annual report, outlining the company’s financial statements, corporate governance, sustainability work and key performance indicators for the financial year. The report, released on April 10, 2026, details the group’s structure and confirms continued adherence to IFRS across Immunovia AB and its subsidiaries.
The annual report emphasizes Immunovia’s mission to lead in pancreatic cancer diagnostics through early detection solutions, positioning this focus as central to its long-term strategy. By presenting a comprehensive overview of operations, management and governance, the company provides stakeholders with transparency on its progress and organizational framework in a critical niche of oncology diagnostics.
The most recent analyst rating on (SE:IMMNOV) stock is a Hold with a SEK0.18 price target. To see the full list of analyst forecasts on Immunovia AB stock, see the SE:IMMNOV Stock Forecast page.
More about Immunovia AB
Immunovia AB is a Swedish diagnostics company focused on early detection of pancreatic cancer. The group operates under IFRS and includes wholly owned subsidiaries Immunovia Inc, Immunovia GmbH and Immunovia Incentive AB, with its headquarters at Medicon Village in Lund, Sweden.
Average Trading Volume: 6,908,449
Technical Sentiment Signal: Strong Sell
Current Market Cap: SEK144.6M
For a thorough assessment of IMMNOV stock, go to TipRanks’ Stock Analysis page.